Login to Your Account


No end in sight?

DUBLIN – The epic CRISPR/Cas9 patent wars took another intriguing twist this week, when the European Patent Office (EPO) revoked a Broad Institute European patent, EP 2771468 B1, on the basis that it lacked priority over novel art. The Broad Institute immediately stated its intention to appeal the decision.

more »


Opinion


Partners in Focus